Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Annexon, Inc. (NASDAQ:ANNXGet Free Report) have been assigned a consensus rating of “Buy” from the six analysts that are presently covering the company, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have covered the stock in the last year is $15.33.

A number of equities analysts have recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $16.00 target price on shares of Annexon in a research report on Tuesday, June 4th. Wells Fargo & Company lowered their target price on Annexon from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, May 15th. JPMorgan Chase & Co. raised their price target on Annexon from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Monday, April 1st. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Annexon in a research report on Tuesday, June 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research note on Wednesday, June 5th.

Check Out Our Latest Analysis on Annexon

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. raised its position in shares of Annexon by 78.2% in the first quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock valued at $48,000 after purchasing an additional 2,949 shares during the period. Tower Research Capital LLC TRC grew its stake in Annexon by 53.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,924 shares of the company’s stock valued at $54,000 after buying an additional 4,141 shares during the last quarter. Comerica Bank bought a new position in Annexon in the 1st quarter valued at about $72,000. ProShare Advisors LLC acquired a new stake in Annexon during the first quarter worth approximately $87,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Annexon during the first quarter worth approximately $98,000.

Annexon Stock Performance

ANNX opened at $5.72 on Tuesday. Annexon has a twelve month low of $1.57 and a twelve month high of $8.40. The firm has a market cap of $528.59 million, a price-to-earnings ratio of -3.89 and a beta of 1.30. The firm’s 50-day simple moving average is $5.13 and its 200-day simple moving average is $4.79.

Annexon (NASDAQ:ANNXGet Free Report) last posted its earnings results on Monday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.11. As a group, sell-side analysts anticipate that Annexon will post -0.99 EPS for the current fiscal year.

Annexon Company Profile

(Get Free Report

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

Featured Articles

Analyst Recommendations for Annexon (NASDAQ:ANNX)

Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.